Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
Stocks in play: Aptose Biosciences Inc.
Today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose’s Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in ...
Aptose Biosciences' leukemia drug shows early promise
Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...